Two different mechanisms for activation of cyclic PIP synthase: By a G protein or by protein tyrosine phosphorylation

Biological Chemistry

Volumn 381, Issue 2, 2000, Pages 145-153

  Wasner, Heinrich K ^a   Gebel, Marion ^a   Hucken, Sabine ^a   Schaefer, Monika ^a   Kincses, Monika ^a  

^a LEIBNIZ CENTER FOR DIABETES RESEARCH AT HEINRICH HEINE UNIVERSITY DÜSSELDORF   (Germany)

Author keywords

Cyclic AMP antagonist; G protein; Insulin action; Protein tyrosine phosphatase; Tyrosine kinase

Indexed keywords

BIGUANIDE; CYCLIC AMP; CYCLIC PROSTAGLANDYLINOSITOL PHOSPHATE SYNTHASE; FLUORIDE; GUANINE NUCLEOTIDE BINDING PROTEIN; GUANOSINE TRIPHOSPHATE DERIVATIVE; MEMBRANE ENZYME; NORADRENALIN; PROSTAGLANDIN E; PROSTAGLANDINYLINOSITOL CYCLIC PHOSPHATE; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; SYNTHETASE; TYRPHOSTIN; UNCLASSIFIED DRUG; VANADIC ACID;

ANIMAL TISSUE; ARTICLE; BIOSYNTHESIS; BRAIN; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; ENZYME STABILITY; GEL FILTRATION; HEART; IC 50; INTESTINE; KIDNEY; LIVER; LUNG; MALE; MICHAELIS CONSTANT; NONHUMAN; PRIORITY JOURNAL; RAT; SKELETAL MUSCLE; SPLEEN; TESTIS;

ANIMALIA;

EID: 0034012713     PISSN: 14316730     EISSN: None     Source Type: Journal    
DOI: 10.1515/BC.2000.020     Document Type: Article

References (27)

1. Amini, H., and Wasner, H.K. (1996a). The mediator of insulin action, cyclic PIP, is biosynthesized from prostaglandin E and activated inositol polyphosphate in rat liver plasma membranes; regulatory mechanisms controlling the activity of cyclic PIP synthase (abstract). Exp. Clin. Endocrinol. Diabetes 104, A11.
2. Amini, H., and Wasner, H.K. (1996b). Cyclic PIP, a mediator of insulin action and cyclic PIP synthase activated by antidiabetic and antihypertensive drugs (abstract). Exp. Clin. Endocrinol. Diabetes 704, A13.
3. 2-/ phospholipid-dependent protein kinases. Proc. Natl. Acad. Sci. USA 88, 6696-6700.
4. David, M., Romero, G., Zhang, Z., Dixon, J.E., and Lamer, A.C. (1993). In vitro activation of the transcription factor ISGF3 by interferon α involves a membrane-associated tyrosine phosphatase and tyrosine kinase. J. Biol. Chem. 268, 6593-6599.
5. Dominguez, L., Davidoff, A., Srinivas, P., Standley, P., Walsh, M., and Sowers, J. (1996). Effects of metformin on tyrosine kinase activity, glucose transport, and intracellular calcium in rat vascular smooth muscle. Endocrinology 137, 113-121.
6. Errasfa, M., and Stern, A. (1994). Inhibition of epidermal growth factor-dependent protein tyrosine phosphorylation by phorbol myristate acetate is mediated by protein tyrosine phosphatase activity. FEBS Lett. 339, 7-10.
7. Faure, R., Baquiran, G., Bergeron, J.M., and Posner, B.I. (1992). The dephosphorylation of insulin and epidermal growth factor receptor. J. Biol. Chem. 267, 11215-11221.
8. Gypakis, A., and Wasner, H.K. (1996). Biosynthesis of activated inositol phosphate, a novel class of inositol phosphates (abstract). Exp. Clin. Endocrinol. 104, A18.
9. Kaiser, A.M., Wasner, H.K., and Spindler, K.D. (1998). Synthesis and action of the cyclic AMP antagonist prostaglandylinositol cyclic phosphate (cyclic PIP), in Dictyostelium discoideum. Biol. Chem. 379, 727-730.
10. Majerus, P.W. (1992). Inositol phosphate biochemistry. Annu. Rev. Biochem. 61, 225-250.
11. Ohki, S., Ogino, N., Yamamoto, S., and Hayaishi, O. (1979). Prostaglandin hydroperoxidase, an integral part of prostaglandin endoperoxide synthase from bovine vesicular gland microsomes. J. Biol. Chem. 254, 829-836.
12. Pfeuffer, T. (1979). Guanine nucleotide-controlled interactions between components of adenylate cyclase. FEBS Lett. 101, 85-89.
13. Pfeuffer, T., and Helmreich, E.J.M. (1975). Activation of pigeon erythrocyte membrane adenylate cyclase by guanylnucleotide analogues and separation of a nucleotide binding protein. J. Biol. Chem. 250, 867-876.
14. Rosen, O.M., and Lebwohl, D.E. (1988). Polylysine activates and alters the divalent cation requirements of the insulin receptor tyrosine kinase. FEBS Lett. 237, 397-401.
15. Rosen, O.M., Herrera, R., Olowe, Y., Petruzzelli, L.M., and Cobb, M.H. (1983). Phosphorylation activates the insulin receptor tyrosine protein kinase. Proc. Natl. Acad. Sci. USA 80, 3237-3240.
16. Singer, W.D., Brown, H.A., and Sternweis, P.C. (1997). Regulation of eukaryotic phosphatidylinositol-specific phospholipase C and phospholipase D. Annu. Rev. Biochem. 66, 475-509.
17. Swarup, G., Cohen, S., and Garbers, D.L. (1982). Inhibition of membrane phosphotyrosyl-protein phosphatase activity by vanadate. Biochem. Biophys. Res. Commun. 107, 1104-1109.
18. Wasner, H.K. (1975). Regulation of protein kinase and phosphoprotein phosphatase by cyclic AMP and cyclic AMP antagonist. FEBS Lett. 57, 60-63.
19. Wasner, H.K. (1976). Preparation of a liver plasma membrane with an adrenalin-responsive adenylyl cyclase after inhibition of prostaglandin synthesis by indomethacin. FEBS Lett. 72, 127-130.
20. Wasner, H.K. (1981). Biosynthesis of cyclic AMP antagonist in hepatocytes from rats after adrenalin-or insulin-stimulation (isolation, purification and prostaglandin E requirement for its synthesis). FEBS Lett. 133, 260-264.
21. Wasner, H.K., and Salge, U. (1987). Prostaglandylinositol cyclic phosphate, an antagonist to cyclic AMP. Adv. Prostaglandin, Thromboxane Leukotriene Res. 17, 691-695.
22. Wasner, H.K., Kaufmann, R., and Lemoine, H. (1992). Mass spectrometric identification of prostaglandylinositol, the dephosphorylated cyclic AMP antagonist, cyclic PIP. Analusis 20, 171-177.
23. Wasner, H.K., Salge, U., and Gebel, M. (1993). The endogenous cyclic AMP antagonist, cyclic PIP: its ubiquity, hormone-stimulated synthesis and identification as prostaglandylinositol cyclic phosphate. Acta Diabetol. 30, 220-232.
24. Wasner, H.K., Weber, S., Partke, H.J., and Amini-Hadi-Kiashar, H. (1994). Indomethacin treatment causes loss of insulin action in rats: involvement of prostaglandins in the mechanism of insulin action. Acta Diabetol. 37, 175-182.
25. Wasner, H.K., Amini-Hadi-Kiashar, H., Gypakis, A., and Niktopoulos, A. (1996a). Cyclic PIP synthase, activated by tyrosine phosphorylation, combines prostaglandin E with activated inositol phosphate to cyclic PIP, a mediator of insulin action (abstract). Exp. Clin. Endocrinol. Diabetes 104 (Suppl. 2), 142.
26. Wasner, H.K., Leßmann, M., Conrad, M., Amini, H., Psarakis, E., and Mir-Mohammad-Sadegh, A. (1996b). Biosynthesis of the endogenous cyclic adenosine monophosphate (AMP) antagonist, prostaglandylinositol cyclic phosphate (cyclic PIP), from prostaglandin E and activated inositol polyphosphate in rat liver plasma membranes. Acta Diabetol. 33, 126-138.
27. Wasner, H.K., Salge, U., Psarakis, E., and Niktopoulos, A. (1997). Insulin resistance, a result of reduced synthesis of cyclic PIP, a mediator of insulin action? Regulation of cyclic PIP synthase activity by oral antidiabetic and antihypertensive drugs. Acta Diabetol. 34, 257-264.